ATS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Author home page(s):
Demetrios Katsaros
Norman J. Snow
Dennis D. Woodhall
Robert Van Bergen
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Katsaros, D.
Right arrow Articles by Van Bergen, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Katsaros, D.
Right arrow Articles by Van Bergen, R.
Related Collections
Right arrowRelated Article

Ann Thorac Surg 1996;61:1131-1135
© 1996 The Society of Thoracic Surgeons

Original Article: Cardiovascular

Tranexamic Acid Reduces Postbypass Blood Use: A Double-Blinded, Prospective, Randomized Study of 210 Patients

Demetrios Katsaros, MD, Mark Petricevic, PhD, Norman J. Snow, MD, Dennis D. Woodhall, MD, Robert Van Bergen, MD

Division of Cardiothoracic Surgery, Fairview Hospital, Cleveland, Ohio

Background. Pharmacologic intervention to minimize postbypass bleeding and blood product transfusions has received increasing attention for both medical and economic reasons.

Methods. Two hundred ten patients were entered into a double-blinded, prospective, randomized study to receive either 10 g of the fibrinolytic inhibitor tranexamic acid before incision (n = 104) or 250 mL of placebo saline solution (n = 106). All subjects requiring cardiopulmonary bypass were deemed suitable, including those having first-time coronary bypass grafting, valve replacement, and reoperation.

Results. There were no statistically significant differences between the groups with respect to demographic or operative characteristics. The tranexamic acid group had a 48% reduction in 24-hour blood drainage (p < 0.001) and received 69% fewer total units of packed red blood cells, 83% fewer total units of plasma, and 75% fewer platelet transfusion units than controls. Only 13 of 104 tranexamic acid patients received blood products versus 33 of 106 controls (p < 0.001). The incidences of thrombotic complications, perioperative myocardial infarction, renal failure, and neurologic complications were not significantly different between the two groups. The tranexamic acid group had 0% mortality versus 1.9% for controls (not significant).

Conclusions. Tranexamic acid is safe and effective in reducing blood loss and blood use in a wide variety of cardiac surgical patients.


Related Article

Discussion
Ann. Thorac. Surg. 1996 61: 1135. [Extract] [Full Text]



This article has been cited by other articles:


Home page
 CirculationHome page
J. R. Brown, N. J.O. Birkmeyer, and G. T. O'Connor
Meta-Analysis Comparing the Effectiveness and Adverse Outcomes of Antifibrinolytic Agents in Cardiac Surgery
Circulation, June 5, 2007; 115(22): 2801 - 2813.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
P. M. Mannucci and M. Levi
Prevention and Treatment of Major Blood Loss
N. Engl. J. Med., May 31, 2007; 356(22): 2301 - 2311.
[Full Text] [PDF]

Home page
 Asian Cardiovasc. Thorac. Ann.Home page
S. G Raja, S. Yousufuddin, F. Rasool, A. Nubi, M. Danton, and J. Pollock
Impact of modified ultrafiltration on morbidity after pediatric cardiac surgery.
Asian Cardiovasc Thorac Ann, August 1, 2006; 14(4): 341 - 350.
[Abstract] [Full Text] [PDF]

Home page
 Anesth. Analg.Home page
B. K. Fiechtner, G. A. Nuttall, M. E. Johnson, Y. Dong, N. Sujirattanawimol, W. C. Oliver Jr., R. S. Sarpal, L. J. Oyen, and M. H. Ereth
Plasma Tranexamic Acid Concentrations During Cardiopulmonary Bypass
Anesth. Analg., May 1, 2001; 92(5): 1131 - 1136.
[Abstract] [Full Text] [PDF]

Home page
 Eur. J. Cardiothorac. Surg.Home page
R. G. Leyh, C. Bartels, E. Joubert-Hubner, J. F.M. Bechtel, and H. H. Sievers
Influence of modified ultrafiltration on coagulation, fibrinolysis and blood loss in adult cardiac surgery
Eur. J. Cardiothorac. Surg., February 1, 2001; 19(2): 145 - 151.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
M. Misfeld, S. Dubbert, S. Eleftheriadis, H.-J. Siemens, T. Wagner, and H.-H. Sievers
Fibrinolysis-adjusted perioperative low-dose aprotinin reduces blood loss in bypass operations
Ann. Thorac. Surg., September 1, 1998; 66(3): 792 - 799.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
P. M. Mannucci
Hemostatic Drugs
N. Engl. J. Med., July 23, 1998; 339(4): 245 - 253.
[Full Text] [PDF]

Home page
 SEMIN CARDIOTHORAC VASC ANESTHHome page
D. Royston
Hemostatic Drugs in Prothrombotic or Hypercoagulable States
Seminars in Cardiothoracic and Vascular Anesthesia, November 1, 1997; 1(4): 376 - 394.
[Abstract] [PDF]

Home page
 J. Thorac. Cardiovasc. Surg.Home page
J. Katoh, K. Tsuchiya, W. Sato, M. Nakajima, and Y. Iida
ADDITIONAL POSTBYPASS ADMINISTRATION OF TRANEXAMIC ACID REDUCES BLOOD LOSS AFTER CARDIAC OPERATIONS
J. Thorac. Cardiovasc. Surg., April 1, 1997; 113(4): 802 - 804.
[Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 1996 by The Society of Thoracic Surgeons.